Sunitinib-induced cardiac hypertrophy and the endothelin axis
Joevin Sourdon, Caterina Facchin, Anaïs Certain, Thomas Viel, Blaise Robin, Franck Lager, Carmen Marchiol, Daniel Balvay, Thulaciga Yoganathan, Judith Favier, Pierre‐Louis Tharaux, Neeraj Dhaun, Gilles Renault, Bertrand Tavitian
Abstract
Early metabolic changes predict sunitinib-induced cardiac remodeling. Endothelin blockade can prevent some but not all cardiotoxic side-effects of sunitinib, in particular left ventricle hypertrophy that appears to be induced by sunitinib through an endothelin-independent mechanism.
Topics & Concepts
Political scienceMedicineLibrary scienceHumanitiesInternal medicinePhilosophyComputer scienceChemotherapy-induced cardiotoxicity and mitigationChronic Myeloid Leukemia TreatmentsPeptidase Inhibition and Analysis